Andere Sprachen Panbela Therapeutics, Inc.

Aktien

A4017G

US69833W4042

SNBP

Verzögert OTC Markets Andere Börsenplätze 19:36:47 26.06.2024			% 5 Tage	% 1. Jan.
0.4009 ^USD	+4.13%		-1.01%	-97.81%

24.06.	Panbela Therapeutics gibt dritte unabhängige Sicherheitsüberprüfung der klinischen Phase-3-Studie ASPIRE bekannt DSMB empfiehlt Fortführung ohne Studienänderung	CI
10.06.	Panbela Therapeutics, Inc. kündigt mündliche Präsentation auf der Digestive Disease Week (DDW) an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification	24.06.
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification	24.06.
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification	24.06.
Panbela Announces Oral Presentation at Digestive Disease Week (DDW)	10.06.
Panbela Announces Oral Presentation at Digestive Disease Week (DDW)	10.06.
Panbela Therapeutics, Inc. Announces Oral Presentation at Digestive Disease Week	10.06.
North American Morning Briefing : The "Everything -2-	17.05.
Panbela Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Panbela Provides Business Update and Reports Q1 2024 Financial Results	15.05.
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac	06.05.
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024	01.05.
Certain Stock Options of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01.05.
Certain Warrants of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01.05.
Certain Common Stock of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01.05.
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week	30.04.
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025	22.04.
Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025	22.04.
Panbela Announces Poster Presentation at American Association for Cancer Research	18.04.
Panbela Announces Poster Presentation at American Association for Cancer Research	18.04.
Panbela Announces Poster Presentation At American Association for Cancer Research	18.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Panbela Therapeutics, Inc.

Aktien

A4017G

US69833W4042

SNBP

Andere Sprachen

Filter